BACKGROUND: Contrast-induced acute kidney injury (CI-AKI) is an adverse consequence of percutaneous coronary interventions which results in significant morbidity and mortality and adds to the costs of diagnostic and interventional cardiology procedures. Various pathophysiological mechanisms have been proposed for CI-AKI and various agents tested for its prevention. There is currently a general agreement that adequate pre-procedural hydration constitutes the cornerstone of prevention, yet there are reports of the use of some other agents with various efficacies. We prospectively tested IV magnesium sulfate (Mg) for CI-AKI prevention. METHOD AND DESIGN: This study is a prospective, randomized, open-labeled, single-center clinical trial. We randomly assigned 122 consecutive patients to two groups. The first group was the control group with routine treatment (n = 64), and second group was the study group with routine treatment plus IV magnesium sulfate 1 g just before the procedure (n = 62). Serum creatinine was measured before the procedure and 2 days after the procedure. The primary end point was the occurrence of CI-AKI within 48 h. CI-AKI was defined as 0.5 mg/dl or more increase in serum creatinine or 25% or more increase above baseline serum creatinine. There was no difference in definition if both of these parameters were present. RESULTS: The control and study groups were comparable in the overall predicted risk of CI-AKI. Also, the type and volume of the contrast were not significantly different between the two groups. Following angioplasty, CI-AKI occurred in 17 (26.6%) patients in the control group and nine (14.5%) patients in the study group; there was a significant reduction in CI-AKI in the study group (P = 0.01). Additionally, there was no mortality or a need for hemodialysis in either group. CONCLUSION: In primary PCI patients, the prophylactic use of intravenous Mg can be recommended to be added to traditional hydration for CI-AKI prevention.
RCT Entities:
BACKGROUND: Contrast-induced acute kidney injury (CI-AKI) is an adverse consequence of percutaneous coronary interventions which results in significant morbidity and mortality and adds to the costs of diagnostic and interventional cardiology procedures. Various pathophysiological mechanisms have been proposed for CI-AKI and various agents tested for its prevention. There is currently a general agreement that adequate pre-procedural hydration constitutes the cornerstone of prevention, yet there are reports of the use of some other agents with various efficacies. We prospectively tested IV magnesium sulfate (Mg) for CI-AKI prevention. METHOD AND DESIGN: This study is a prospective, randomized, open-labeled, single-center clinical trial. We randomly assigned 122 consecutive patients to two groups. The first group was the control group with routine treatment (n = 64), and second group was the study group with routine treatment plus IV magnesium sulfate 1 g just before the procedure (n = 62). Serum creatinine was measured before the procedure and 2 days after the procedure. The primary end point was the occurrence of CI-AKI within 48 h. CI-AKI was defined as 0.5 mg/dl or more increase in serum creatinine or 25% or more increase above baseline serum creatinine. There was no difference in definition if both of these parameters were present. RESULTS: The control and study groups were comparable in the overall predicted risk of CI-AKI. Also, the type and volume of the contrast were not significantly different between the two groups. Following angioplasty, CI-AKI occurred in 17 (26.6%) patients in the control group and nine (14.5%) patients in the study group; there was a significant reduction in CI-AKI in the study group (P = 0.01). Additionally, there was no mortality or a need for hemodialysis in either group. CONCLUSION: In primary PCI patients, the prophylactic use of intravenous Mg can be recommended to be added to traditional hydration for CI-AKI prevention.
Authors: A S Abizaid; C E Clark; G S Mintz; S Dosa; J J Popma; A D Pichard; L F Satler; M Harvey; K M Kent; M B Leon Journal: Am J Cardiol Date: 1999-01-15 Impact factor: 2.778
Authors: Tien M H Ng; Scott W Shurmur; Mary Silver; Lindsay R Nissen; Edward L O'Leary; Richard S Rigmaiden; Mike Cieciorka; Laura L Porter; Beata A Ineck; Mary E Kline; Susan E Puumala Journal: Int J Cardiol Date: 2005-07-22 Impact factor: 4.164
Authors: Judith Kooiman; Yvo W J Sijpkens; Jean-Paul P M de Vries; Harald F H Brulez; Jaap F Hamming; Aart J van der Molen; Nico J M Aarts; Suzanne C Cannegieter; Hein Putter; Renate Swarts; Wilbert B van den Hout; Ton J Rabelink; Menno V Huisman Journal: Nephrol Dial Transplant Date: 2014-02-27 Impact factor: 5.992
Authors: Somjot S Brar; Albert Yuh-Jer Shen; Michael B Jorgensen; Adam Kotlewski; Vicken J Aharonian; Natasha Desai; Michael Ree; Ahmed Ijaz Shah; Raoul J Burchette Journal: JAMA Date: 2008-09-03 Impact factor: 56.272
Authors: Mehmet Kanbay; Adrian Covic; Steven G Coca; Faruk Turgut; Ali Akcay; Chirag R Parikh Journal: Int Urol Nephrol Date: 2009-04-25 Impact factor: 2.370
Authors: R E Katholi; W T Woods; G J Taylor; C L Deitrick; K A Womack; C R Katholi; W P McCann Journal: Am J Kidney Dis Date: 1998-07 Impact factor: 8.860
Authors: Mary Elizabeth Money; Aghiles Hamroun; Yan Shu; Carolyn Matthews; Sara Ahmed Eltayeb; Giuliano Ciarimboli; Christine Noel Metz Journal: Front Oncol Date: 2021-02-26 Impact factor: 6.244